Endocrine Pathology

, Volume 11, Issue 3, pp 205–213 | Cite as

Bcl-2 gene family in endocrine pathology: A review

Review

Abstract

Bcl-2 is a member of a large multigene family, which includes genes that can inhibit or promote apoptosis. The regulation of apoptosis is achieved by homo- or heterodimerization of their proteins through four highly conserved domains. Bcl-2 protein is a strong cell death suppressor in a wide range of cell types and under a variety of stimuli. Bcl-2 and the other members of this family are differentially expressed in the endocrine glands and disregulation of their expression seems to contribute to the neoplastic transformation in these organs. The significance of bcl-2 and the related proteins for endocrine pathology at the experimental and clinical level is reviewed in this article.

Key Words

Apoptosis bax bcl-2 immunohistochemistry tumors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gluksann A. Cell death in normal vertebrate ontogeny. Biol Rev 26:59–86, 1951.CrossRefGoogle Scholar
  2. 2.
    Saunders JW Jr. Death in embryonic systems. Science 154:604–612, 1966.PubMedCrossRefGoogle Scholar
  3. 3.
    Schwartz LM, Osborne BA. Programmed cell death, apoptosis and killer genes. Immunology Today, 14:582–590, 1993.PubMedCrossRefGoogle Scholar
  4. 4.
    Kontogeorgos G, Kovacs K. Apoptosis in endocrine glands. Endocr Pathol 6:257–265, 1995.PubMedGoogle Scholar
  5. 5.
    Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the Bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and the outer mitochondrial membranes. Cancer Res 53:4701–4714, 1993.PubMedGoogle Scholar
  6. 6.
    Tsujimoto Y, Croce CM. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214–5218, 1986.PubMedCrossRefGoogle Scholar
  7. 7.
    McDonnell TJ, Tronosco P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940–6944, 1992.PubMedGoogle Scholar
  8. 8.
    Pezzela F, Turley H, Kuzu I, Tunkegar MF, Dunnil MS, Pierce CB, Harris A, Gatter KC, Mason DY. Bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329:690–694, 1993.CrossRefGoogle Scholar
  9. 9.
    Lu Q-L, Poulsom R, Wong L, Hanby AM. BCL-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 169:431–437, 1993.PubMedCrossRefGoogle Scholar
  10. 10.
    Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535–540, 1994.PubMedGoogle Scholar
  11. 11.
    Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res 17:2499–2506, 1997.PubMedGoogle Scholar
  12. 12.
    Reed J. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1–6, 1994.PubMedCrossRefGoogle Scholar
  13. 13.
    Graig RW. The BCL-2 gene family. Semin Cancer Biol 6:35–43, 1995.CrossRefGoogle Scholar
  14. 14.
    Kroemer G. The protooncogene bcl-2 and its role in regulating apoptosis. Nature Med 3:614–620, 1997.PubMedCrossRefGoogle Scholar
  15. 15.
    Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321–333, 1994.PubMedCrossRefGoogle Scholar
  16. 16.
    Huang DC, O’Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 16:4628–4638, 1997.PubMedCrossRefGoogle Scholar
  17. 17.
    Korsmeyer SJ. Regulators of cell death. Trends in Genetics 11:101–105, 1995.PubMedCrossRefGoogle Scholar
  18. 18.
    Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602–3610, 1990.PubMedGoogle Scholar
  19. 19.
    Garcia I, Martinou I, Tsujimoto Y, Martinou JC. Prevention of programmed cell death of sympathetic neurons by the bcl-2 protooncogene. Science 258:302–304, 1992.PubMedCrossRefGoogle Scholar
  20. 20.
    Korsmeyer SJ. Bcl-2: an antidote to programmed cell death. Cancer Surveys 15:105–118, 1992.PubMedGoogle Scholar
  21. 21.
    Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. Pathol 172:337–342, 1994.CrossRefGoogle Scholar
  22. 22.
    Branet F, Brousset P, Krajewski S, Schlaifer D, Selves J, Reed JC, Caron P. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J Clin Endocrinol Metab 81:2726–2730, 1996.PubMedCrossRefGoogle Scholar
  23. 23.
    Riou C, Tonoli H, Bernier-Valentin F, Rabilloud R, Fonlupt P, Rousset B. Susceptibility of differentiated thyrocytes in primary culture to undergo apoptosis after exposure to hydrogen peroxide: relation with the level of expression of apoptosis regulatory proteins, Bcl-2 and Bax. Endocrinology 140:1990–1997, 1999.PubMedCrossRefGoogle Scholar
  24. 24.
    Moore D, Ohene-Fianko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology 32:35–42, 1998.PubMedCrossRefGoogle Scholar
  25. 25.
    Brocker M, de Buhr I, Papageorgiou G, Schatz H, Derwahl M. Expression of apoptosis-related proteins in thyroid tumors and thyroid carcinoma cell lines. Exp Clin Endocrinol Diabetes 104 (Suppl) 4:20–23, 1996.PubMedCrossRefGoogle Scholar
  26. 26.
    Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 73:139–143, 1996.PubMedGoogle Scholar
  27. 27.
    Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, Bergholm U, Coggi G. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoama. Hum Pathol 26:945–950, 1995.PubMedCrossRefGoogle Scholar
  28. 28.
    Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 75:537–541, 1997.PubMedGoogle Scholar
  29. 29.
    Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hürthle cell) carcinomas of the thyroid. Am J Surg Pathol 20:686–694, 1996.PubMedCrossRefGoogle Scholar
  30. 30.
    Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC, Eusebi V. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Arch 430:125–130, 1997.PubMedCrossRefGoogle Scholar
  31. 31.
    Amling M, Neff L, Tanaka S, Inoue D, Kuida K, Weir E, Philbrick WM, Broadus AE, Baron R. Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J Cell Biol 136:205–213, 1997.PubMedCrossRefGoogle Scholar
  32. 32.
    Suda N. Parathyroid hormone-related protein (PTHrP) as a regulating factor of endochondral bone formation. Oral Dis 3:229–231, 1997.PubMedCrossRefGoogle Scholar
  33. 33.
    Naccarato AG, Marcocci C, Miccoli P, Bonadio AG, Gianferotti L, Vignali E, et al. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues. J Endocrinol Invest 21:136–141, 1998.PubMedGoogle Scholar
  34. 34.
    Wang W, Johansson H, Kvasnicka T, Farnebo LO, Grimelius L. Detection of apoptotic cells and expression of Ki-67 antigen, Bcl-2, p53 oncoproteins in human parathyroid adenoma. APMIS 104:789–796, 1996.PubMedCrossRefGoogle Scholar
  35. 35.
    Vargas MP, Vargas HI, Kleiner DE, Merino MJ. The role of prognostic markers (MIB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 10:12–17, 1997.PubMedGoogle Scholar
  36. 36.
    Fogt, F, Vortmeyer AO, Poremba C, Minda M, Harris CA, Tomaszewski JE. bcl-2 expression in normal adrenal glands and in adrenal neoplasms. Mod Pathol 11:716–720, 1998.PubMedGoogle Scholar
  37. 37.
    Ando T, Shibata H, Suzuki T, Kurihara I, Hayashi K, Hayashi M, Saito I, Kawabe H, Tsujioka M, Saruta T. The possible role of apoptosis-suppressing genes, bcl-2 and mcl-1/EAT in human adrenal tumors. Endocr Res 24:955–960, 1998.PubMedGoogle Scholar
  38. 38.
    Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 146:1309–1319, 1995.PubMedGoogle Scholar
  39. 39.
    Krajewski S, Krajewska M, Reed JC. Immunohistochemical analysis of in vivo patterns of Bak expression, a proapoptotic member of the Bcl-2 protein family. Cancer Res 56:2849–2855, 1996.PubMedGoogle Scholar
  40. 40.
    Bouwens L, De Blay E. Islet morphogenesis and stem cell markers in rat pancreas. J Histochem Cytochem 44:947–951, 1996.PubMedGoogle Scholar
  41. 41.
    Penault-Llorca F, Bouabdallah R, Devilard E, Charton-Bain MC, Hassoun J, Birg F, Xerri L. Analysis of BAX expression in human tissues using the anti-BAX, 4F11 monoclonal antibody on paraffin sections. Pathol Res Pract 194:457–464, 1998.PubMedGoogle Scholar
  42. 42.
    Mizuno N, Yoshitomi H, Ishida H, Kuromi H, Kawaki J, Seino Y, Seino S. Altered bcl-2 and bax expression and intracellular Ca2+ signaling in apoptosis of pancreatic cells and the impairment of glucose-induced insulin secretion. Endocrinology 139:1429–1439, 1998.PubMedCrossRefGoogle Scholar
  43. 43.
    Iwahashi H, Hanafusa T, Eguchi Y, Nakajima H, Miyagawa J, Itoh N, et al. Cytokine-induced apoptotic cell death in a mouse pancreatic beta-cell line: inhibition by Bcl-2. Diabetologia 39:530–536, 1996.PubMedGoogle Scholar
  44. 44.
    Rabinovitch A, Suarez-Pinzon W, Strynadka K, Ju Q, Edelstein D, Brownlee M, Korbutt GS, Rajotte RV. Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction. Diabetes 48:1223–1229, 1999.PubMedCrossRefGoogle Scholar
  45. 45.
    Woloschak M, Yu A, Xiao J. Molecular and cellular responses to DNA damage in a murine pituitary adenoma cell line. Mol Cell Endocrinol 119:61–68, 1996.PubMedCrossRefGoogle Scholar
  46. 46.
    Kulig E, Jin L, Qian X, Horvath E, Kovacs K, Stefaneanu L, Scheithauer BW, Lloyd RV. Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol 154:767–774, 1999.PubMedGoogle Scholar
  47. 47.
    Kontogeorgos G, Sambaziotis D, Kapranos N. Bcl-2 and bax expression and correlation with apoptosis in pituitary adenomas. Endocr Pathol 9:399–400, 1998.Google Scholar
  48. 48.
    Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A. Apoptosis in human pituitary adenomas: a morphologic and in situ endlabeling study. Modern Pathol 10:921–926, 1997.Google Scholar
  49. 49.
    Brambilla E, Negoescu A, Gazzeri S, Lantuejou S, Moro D, Brambilla C, Coll J-L. Apoptosis-related factors p53, bcl-2 and bax in neuroendocrine lung tumors. Am J Pathol 149:1941–1952, 1996.PubMedGoogle Scholar
  50. 50.
    Jiang SX, Kameya T, Shinada J, Yoshimura H. The significance of frequent and independent p53 and bcl-2 expresion in large-cell neuroendocrine carcinomas of the lung. Mod Pathol 12:362–369, 1999.PubMedGoogle Scholar
  51. 51.
    Merry DE, Veis DJ, Hickey WF, Korsmeyer SJ. Bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. Development 120:301–311, 1994.PubMedGoogle Scholar
  52. 52.
    Zhang KZ, Westberg JA, Hollta E, Anderson LC. Bcl-2 regulates neural differentiation. Proc Natl Acad Scie USA 93:4504–4508, 1996.CrossRefGoogle Scholar
  53. 53.
    Reed JC, Meister L, Tanaka S Cuddy M, Yum S, Geyer C, Pleasure D. Different expression of bcl-2 oncoprotein levels in neuroblastoma and other human tumor cell lines on neural origin. Cancer Res 51:6529–6538, 1991.PubMedGoogle Scholar
  54. 54.
    Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135–138, 1995.PubMedCrossRefGoogle Scholar
  55. 55.
    Krajewski S, Chatten J, Hanada M, Reed JC. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein of bclp. Lab Invest 72:42–54, 1995.PubMedGoogle Scholar
  56. 56.
    Moll I, Gillardon F, Waltering S, Smelz M, Moll R. Differences of bcl-2 protein expression between Merkel cells and Merkel cell carcinomas. J Cutan Pathol 23:109–117, 1996.PubMedCrossRefGoogle Scholar
  57. 57.
    Van den Oord JJ, Vandeghinste N, Ley MD, Wolf-Peeters CD. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 145:294–300, 1994.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2000

Authors and Affiliations

  1. 1.Department of Pathology, Division of Molecular PathologyAmalia Fleming HospitalMelissia
  2. 2.Department of PathologyG. Gennimatas Athens General HospitalAthensGreece

Personalised recommendations